ArticlesOutcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial
Introduction
Invasive procedures have become increasingly common early after an episode of unstable coronary-artery disease, even in patients who are clinically stabilised.1 The 6-month results of the FRISC II (Fast Revascularisation during Instability in Coronary artery disease) invasive trial2 showed a reduction in the composite endpoint of death or myocardial infarction with an invasive strategy in patients with unstable coronary-artery disease and signs of ischaemia as shown by electrocardiography (ECG) or rises in biochemical markers of myocardial damage. These results provoked much debate because two previous large-scale randomised trials had not shown similar results.3, 4 The FRISC II medical trial showed that, within the non-invasive strategy group, extended treatment with dalteparin for 3 months significantly lowered the risk of death, myocardial infarction, and need for revascularisation; thus, this approach might be an alternative strategy.5 The endpoint of myocardial infarction could be invalid because detection, definition, and impact of myocardial infarction differ according to whether it occurs during revascularisation procedures (as in most events in the group treated by the invasive strategy) or spontaneously (as in most events in the group treated non-invasively). Thus, further documentation was needed of the results of the invasive versus non-invasive comparison in the FRISC II trial for mortality only, long-term risk of myocardial infarction, and the long-term outcome among patients treated with dalteparin or placebo. The outcome of the continued follow-up will influence whether the FRISC II invasive trial changes the current treatment guidelines for unstable coronary-artery disease, which will have important consequences for management of patients and for treatment costs. We report here the 1-year results of the randomised invasive versus non-invasive strategy in terms of death, myocardial infarction, and the need for readmission and revascularisation procedures and the outcome in the long-term dalteparin versus placebo cohorts and in predefined subgroups based on commonly used risk indicators.
Section snippets
Patients
Patients were eligible for inclusion if they had symptoms of ischaemia that were increasing or occurring at rest or raised the suspicion of acute myocardial infarction, with the last episode preceding the first dose of dalteparin or standard heparin by less than 48 h. Furthermore, myocardial ischaemia had to be verified by ECG (ST-segment depression ≥0·1 mV or T-wave inversion ≥0·1 mV), or by raised biochemical markers (creatine kinase MB isoenzyme >6 μg/L, troponin T ≥0·10 μg/L, qualitative
Characteristics of patients and procedures done
2457 patients were randomly assigned the invasive or the non-invasive regimen and 3 months' treatment with dalteparin or placebo. In January, 2000, complete information on vital status was available from 2456 patients with a last contact at least 335 days after randomisation. We lacked information on vital status and myocardial infarction at 12 months for one patient from the non-invasive group and information on myocardial infarction for three patients in the invasive group because of
Discussion
The most important new finding in this 1-year follow-up of the invasive versus non-invasive comparison in the FRISC II trial is the significant and clinically relevant absolute and relative reductions in 1-year mortality when an invasive strategy is adopted. Furthermore, the survival analysis indicates a continuously increasing separation of the event rates. The 1-year follow-up documents a treatment alternative—the invasive strategy—that is able to reduce long-term mortality in unstable
References (28)
- et al.
One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial: a randomized commparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q-wave myocardial infarction
J Am Coll Cardiol
(1995) - et al.
Acute coronary syndromes, unstable angina and non-Q-wave myocardial infarction
Circulation
(1998) Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
Lancet
(1999)- et al.
Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy: Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial
N Engl J Med
(1998) Long-term low molecular mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
Lancet
(1999)Collaborative overview of randomised trials of antiplatelet therapy—I prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
BMJ
(1994)- et al.
Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis
JAMA
(1996) Clinical trials of low molecular mass heparin
Am J Cardiol
(1999)Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study
Lancet
(1997)Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
N Engl J Med
(1998)
Inhibition of platelet glycoprotien IIb/IIIa with eptifibatide in patients with acute coronary syndromes
N Engl J Med
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
Lancet
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Trialists Collaboration
Lancet
Twelve-year follow-up of survival in the randomized European Coronary Surgery Study
N Engl J Med
Cited by (641)
Complete Revascularization in Non–ST-Segment Elevation Acute Coronary Syndrome: For Now, Just Do It
2024, JACC: Cardiovascular InterventionsInvasive Cardiac Therapies in Older People–Can We Raise the Bar?
2024, Journal of Cardiothoracic and Vascular AnesthesiaLong-Term Outcomes of Invasive vs Conservative Strategies for Older Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
2023, Journal of the American College of CardiologyAcute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy
2022, Biomedicine and PharmacotherapyClinical implications of diabetes mellitus in patients with acute coronary syndrome: Prognostic role and use of new P2Y<inf>12</inf> receptor inhibitors
2022, Diabetes Research and Clinical PracticePrognostic Value of Coronary CT Angiography in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
2021, Journal of the American College of CardiologyCitation Excerpt :In this context, it should be noted that all VERDICT patients underwent ICA-guided coronary revascularization including heart team–defined referral to coronary artery bypass graft according to contemporary guidelines. The landmark FRISC-II (FRagmin and Fast Revascularisation During Instability in Coronary Artery Disease II) trial published 20 years ago documented that a routine invasive treatment strategy conveyed a reduced mortality, which most likely was mediated by revascularization of patients with left main stem and/or multivessel disease (17,18). In high-risk NSTEACS patients, further improvements of treatment algorithms are urgently needed, and our results suggest that strategies that could include first-line coronary CTA warrant further study.
Information on other investigators and committee members is given at the end of the paper